STOCKS TELEGRAPH

Tag: ARTL

  • 3 Stocks to Watch Right Now: Liveperson Inc (LPSN), Hillcrest Energy Technologies Ltd. (HLRTF), Artelo Biosciences Inc (ARTL)

    3 Stocks to Watch Right Now: Liveperson Inc (LPSN), Hillcrest Energy Technologies Ltd. (HLRTF), Artelo Biosciences Inc (ARTL)

    Recent transformations across the investment landscape are affecting how market participants interpret prospects among smaller and emerging businesses. Changes in stock performance and noticeable shifts in trading behavior frequently mirror adjustments in investor sentiment. Careful observation of volatility trends, momentum indicators, and broader market outlook can provide valuable clues about how these companies are positioning themselves amid evolving market forces.

    Liveperson Inc (LPSN)

    The stock of Liveperson Inc (NASDAQ: LPSN) has decreased by -4.33% when compared to last closing price of $3.0. Despite this, the company has experienced a -6.51% fall in its stock price over the last five trading sessions, with a -5.28% drop in the past month, and a -41.78% fall in the past quarter. The volatility ratio for the week is 7.90%, and the volatility levels for the past 30 days are at 7.16% for LPSN. The simple moving average for the past 20 days is -1.39% for LPSN’s stock, with a -66.37% simple moving average for the past 200 days.

    LPSN Trading at -11.76% from the 50-Day Moving Average

    After a stumble in the market that brought LPSN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with 86.71% of loss for the given period. Volatility was left at 7.16%, however, over the last 30 days, the volatility rate increased by 7.90%.

    Hillcrest Energy Technologies Ltd. (HLRTF)

    To expand market visibility, Hillcrest Energy Technologies Ltd. (HLRTF) has engaged multiple investor relations and media partners to promote awareness of its technology platform and strategic progress. These efforts include campaigns across financial media platforms, digital marketing channels, and industry-focused interviews designed to highlight the company’s power electronics innovations.

    Market Momentum

    The stock is currently trading at $0.1249, down 4.66% on March 10, with trading volume of 6,000 shares compared with an average volume of more than 206,000 shares. Lower volume sessions can sometimes indicate limited trading activity rather than significant changes in investor sentiment.

    Corporate Communications

    Through ongoing investor outreach programs, the company aims to communicate product developments, partnerships, and commercialization milestones to a broader investment audience.

    Sector Outlook

    In the clean-tech sector, increased visibility often plays a critical role in attracting strategic partners and institutional investors interested in emerging electrification technologies.

    Artelo Biosciences Inc (ARTL)

    Artelo Biosciences Inc (NASDAQ: ARTL)‘s stock price has soared by 5.41% in relation to the previous closing price of $3.51. Nevertheless, the company has seen a gain of 12.12% in its stock price over the last five trading days, with a -16.10% drop in the past month, and a -32.97% drop in the past quarter. The volatility ratio for the week is 12.05%, and the volatility levels for the past 30 days are at 10.87% for ARTL. The simple moving average for the past 20 days is 0.09% for ARTL’s stock, with a -76.66% simple moving average for the past 200 days.

    ARTL Trading at -12.70% from the 50-Day Moving Average

    After a stumble in the market that brought ARTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with 95.69% of loss for the given period. Volatility was left at 10.87%; however, over the last 30 days, the volatility rate increased by 12.05%

  • Artelo Biosceinces Inc. (ARTL) Under Corrections After Upsurge on Positive Results from Lead Program

    The development stage biopharma, Artelo Biosceinces Inc. (ARTL) was trending on April 13, due to positive results from its lead program in cancer-related Cachexia. The announcement of the results caused the stock to soar by 20.38% during the regular session on Wednesday. But the upsurge was ultimately followed by a fall in the after hours. Thus, after surging up to $0.5056 at the end of regular trading, ARTL declined to $0.4588. The stock hence reported a downtrend of 9.26% in the after-hours session.

    ARTL’s Positive Pre-Clinical Results

    Source: UNH Manchester

    The company’s lead program showed that ART27.13 which is in clinical development for cancer-related anorexia demonstrated positive pre-clinical results in cancer-induced cachexia as well. Cachexia is muscle degeneration induced by cancer.

    The results showed ART27-13’s potential in protecting human muscle cells from cancer cachexia. This shows the second mechanism of action of the candidate in addition to the first mechanism of action for treating appetite loss and body weight regulation.

    According to VP Translational Science, ARTL, Saoirse O’Sullivan, this shows ART27.13’s capability of reducing the negative effects of chemicals produced by multiple cancers on human muscles. Hence, the company plans to work on translating the results into its ongoing CAReS study. The Cancer Appetite Recovery Study (CAReS) is currently in the final stage of cohort 3 enrollment at six sites in the UK and Ireland.

    Healthcare Stocks

    Healthcare stocks have been under the light recently with increased focus from investors. The reason for this focus is the ongoing instability and widespread volatility in the market. Russia-Ukraine conflict, China-US audit issue, supply chain hurdles, and rising interest rates on top of hiking inflation, all are the reasons for instability in the market. Therefore, to make safer bets, investors are focusing on stocks that are not impacted by the situation too much.

    Healthcare stock thus, fit the resume.

    ARTL’s Progress & Outlook

    With multiple milestones achieved in 2021, the company is currently looking to a number of data readouts in 2022. Data from CAReS study Phase 1 is expected in the first half of 2022 while the Phase 2 data readout is in the second half of the year. Moreover, the company also expected to complete the progress of preclinical research to support the initiation of human trials for both ART26.12 and ART12.11.

    With $25.6 million in cash and marketable securities at the end of 2021, ARTL has enough cash to support operations into H2 2023.

  • Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Seneca Biopharma Inc. (SNCA), a Biotechnology company, rose about 0.2% at $0.96 in pre-market trading Friday after declaring merger agreement with Leading BioSciences, Inc. under which a wholly owned subsidiary of Seneca will merge with LBS in an all-stock transaction.

    Palantir Technologies Inc. (PLTR) lost over -3.97% at $26.15 in pre-market trading Friday December 18, 2020 after reporting that it will hold its inaugural “Live Demo Day” on Tuesday, January 26, 2021 at 4:30pm ET.

    Atossa Therapeutics Inc. (ATOS) stock plunged -0.02% to $0.86 in the pre-market trading following its declaration of pricing of $14.0 million registered direct offering priced at-the-market. The most recent rating by Maxim Group, on January 26, 2018, is a Buy.

    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading down -6.27% at $23.9 at the time of writing. The company recently revealed an update following its test flight on December 12, 2020. Company’s 52-week ranged between $9.06 to $42.49. Analysts have a consensus price target of $19.

    BlackBerry Limited (BB), a Software – Infrastructure company, dropped about -4.36% at $7.9 in pre-market trading Friday after releasing its financial results for the three months ended November 30, 2020

    Before the trading started on December 18, 2020, Uxin Limited (UXIN) is up 4.5% to reach $1.16 following its announcement of unaudited financial results for the quarter ended September 30, 2020. It has been trading in a 52-week range of $0.72 to $3.07.

    Coeur Mining Inc. (CDE) stock plunged -2.98% to $10.76 in the pre-market trading. The firm recently revealed details of the expansion of its Rochester silver-gold mine in Nevada, reflecting significant reserve growth and the benefits of a larger-scale expansion project. The most recent rating by Noble Capital Markets, on September 14, 2020, is an Outperform.

    Novan Inc. (NASDAQ: NOVN) shares are trading up 6.25% at $0.68 at the time of writing. The company lately reported that it has enrolled 525 patients of the approximately 850 patients expected to enroll in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206. Company’s 52-week ranged between $0.22 to $3.72.

    CNS Pharmaceuticals Inc. (CNSP), a Biotechnology company, rose about 15.2% at $2.88 in pre-market trading Friday after announcing FDA approval of IND application for its brain cancer drug candidate Berubicin.

    United States Steel Corporation (X) stock moved down -4.26 percent to $17.77 in the pre-market trading after reporting that fourth quarter 2020 adjusted EBITDA is expected to be approximately $55 million and expected fourth quarter 2020 adjusted diluted loss per share to be approximately ($0.85).

    BioCardia Inc. (BCDA) lost over -6.09% at $4.01 in pre-market trading Friday December 18, 2020 following an announcement from the firm that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial.

    Before the trading started on December 18, 2020, Ampio Pharmaceuticals Inc. (AMPE) is up 8.43% to reach $1.93 after revealing the completion of its Phase I clinical trial and initiation of the first steps for a global Phase II clinical trial for intravenous (“IV”) Ampion treatment in COVID-19 patients. It has been trading in a 52-week range of $0.31 to $1.69.

    Drive Shack Inc. (NYSE: DS) shares are trading up 5.47% at $3.47 at the time of writing following the opening of its 65,000-square-foot entertainment golf venue located in Orlando. Company’s 52-week ranged between $0.86 to $4.19. Analysts have a consensus price target of $4.

    IZEA Worldwide Inc. (IZEA) tumbled over -3.7% at $1.04 in pre-market trading today. The company recently reported that it has just been awarded a mid-six figure contract from a Fortune 500 Manufacturer.

    Exela Technologies Inc. (XELA), a Software – Application company, rose about 81.87% at $0.66 in pre-market trading Friday after declaring that it has entered into a 5-year, $145 million term loan facility with Angelo Gordon, a global alternative investment firm.

    FedEx Corporation (FDX) stock moved down -2.89 percent to $283.8 in the pre-market trading after declaring strong results for the quarter ended November 30.

    Guardion Health Sciences Inc. (GHSI) stock plunged -2.13% to $0.23 in the pre-market trading. The firm recently declared progress on the introduction of its new vision support/energy drink, Epiq-V, which is under development for the United States and international markets.

    Amyris Inc. (NASDAQ: AMRS) shares are trading up 3.68% at $4.23 at the time of writing. Company’s 52-week ranged between $1.40 to $6.07. Analysts have a consensus price target of $3.35.

    Mereo BioPharma Group plc (MREO), a Biotechnology company, rose about 40.27% at $3.1 in pre-market trading Friday following the declaration of a license and collaboration agreement with Ultragenyx Pharmaceutical Inc. (RARE), for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).

    Surface Oncology Inc. (SURF) gained over 17.51% at $10.0 in pre-market trading Friday December 18, 2020 after revealing exclusive license agreement with GSK for novel immunotherapy program.

    Neovasc Inc. (NVCN) is down more than -8.52% at $0.91 in pre-market hours Friday December 18, 2020 after reporting the publication of peer-reviewed article in EuroIntervention. The stock had jumped over 3.61% to $0.99 in the last trading session.

    BioLineRx Ltd. (BLRX) tumbled over -1.1% at $2.7 in pre-market trading today. The firm lately declared final results from Phase 2a COMBAT/KEYNOTE-202 triple combination study of Motixafortide in second line Metastatic Pancreatic Cancer (PDAC).

    VYNE Therapeutics Inc. (VYNE), a Biotechnology company, rose about 8.05% at $1.88 in pre-market trading Friday after declaring the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA).

    Before the trading started on December 18, 2020, Mesoblast Limited (MESO) is down -26.75% to reach $9.94 after announcing an update on COVID-19 ARDS trial. It has been trading in a 52-week range of $3.12 to $21.28.

    Applied DNA Sciences Inc. (APDN) stock plunged -12.02% to $5.49 in the pre-market trading after reporting consolidated financial results for the full fiscal year and quarter ended September 30, 2020. The most recent rating by H.C. Wainwright, on July 20, 2020, is a Buy.

    Conformis Inc. (NASDAQ: CFMS) shares are trading up 3.8% at $0.6693 at the time of writing. The firm lately revealed the U.S. commercial launch of the Company’s new Cordera™ Match Hip System. Company’s 52-week ranged between $0.50 to $1.66.

    Auris Medical Holding Ltd. (EARS) grew over 1.5% at $2.7 in pre-market trading today. The company recently provided a business update related to the Company’s funding position, its AM-301 program for the protection against airborne pathogens and allergens and the ongoing strategy review process.

    Sonoma Pharmaceuticals Inc. (SNOA) stock moved up 19.79 percent to $9.14 in the pre-market trading following the announcement of partnership with Gabriel Science, LLC for dental.

  • What changed for these 31 stocks in Pre Market Session

    What changed for these 31 stocks in Pre Market Session

    Xenetic Biosciences Inc. (XBIO) stock plunged -15.46% to $2.68 in the pre-market trading following the company’s announcement of $6.0 million registered direct offering priced at-the-market under Nasdaq Rules. The most recent rating by Maxim Group, on January 08, 2020, is a Buy.
    Curis Inc. (CRIS), a Biotechnology company, dropped about -5.72% at $7.25 in pre-market trading Thursday after declaring the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million.
    ZW Data Action Technologies Inc. (CNET) lost over -11.33% at $1.8 in pre-market trading Thursday December 10, 2020 after reporting the official opening of its first live streaming platform in Guangzhou, China.
    Genius Brands International Inc. (GNUS) is up more than 9.74% at $1.69 in pre-market hours Thursday December 10, 2020. The firm recently revealed that it will be presenting at the 13th Annual LD Micro investor conference on Tuesday, December 15th at 10:00 a.m. PST / 1:00 p.m. EST. The stock had dropped over -4.35% to $1.54 in the last trading session.
    Rocket Companies Inc. (RKT), a Mortgage Finance company, rose about 3.09% at $21.71 in pre-market trading Thursday following the release of Clear HOI platform from its subsidiary to mortgage lenders nationwide.
    Intec Pharma Ltd (NTEC) stock moved down -7.76 percent to $4.28 in the pre-market trading. Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma.
    Atossa Therapeutics Inc. (ATOS) gained over 2.31% at $0.8919 in pre-market trading Thursday December 10, 2020 after revealing cannabinoid research collaboration with GW Pharma.
    Nano Dimension Ltd. (NNDM) is up more than 2.25% at $6.82 in pre-market hours Thursday December 10, 2020 following the declaration from the company that it has closed the registered direct offering of 30,000,000 of the Company’s American Depositary Shares at a price of $6.00 per ADS. The stock had dropped over -6.06% to $6.67 in the last trading session.
    Before the trading started on December 10, 2020, Sorrento Therapeutics Inc. (SRNE) is down -2.44% to reach $8.01 following the FDA acceptance of its Investigational New Drug (IND) application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). It has been trading in a 52-week range of $1.55 to $19.39.
    Genetic Technologies Limited (GENE) stock plunged -9.17% to $4.06 in the pre-market trading.
    Greenwich LifeSciences Inc. (GLSI) grew over 46.76% at $83.8 in pre-market trading today after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.
    Lipocine Inc. (LPCN), a Biotechnology company, dropped about -5.3% at $1.25 in pre-market trading Thursday after announcing that the U.S. Food and Drug Administration has granted tentative approval to TLANDO.
    SELLAS Life Sciences Group Inc. (SLS) stock moved up 51.8 percent to $9.7 in the pre-market trading. The biotechnology firm recently revealed exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China.
    Francesca’s Holdings Corporation (NASDAQ: FRAN) shares are trading down -10.68% at $2.51 at the time of writing after receiving court approval of “First Day” motions to support ongoing operations. Company’s 52-week ranged between $1.70 to $19.91. Analysts have a consensus price target of $2.50.
    Oncternal Therapeutics Inc. (ONCT) tumbled over -27.78% at $4.55 in pre-market trading today after announcing that the firm increased its previously declared bought deal to $75.0 million.
    Gran Tierra Energy Inc. (GTE) is down more than -2.83% at $0.35 in pre-market hours Thursday December 10, 2020. The company recently declared a financial update and the Company’s 2021 capital budget and production guidance. The stock had dropped over -5.68% to $0.36 in the last trading session.
    Before the trading started on December 10, 2020, Fisker Inc. (FSR) is down -4.04% to reach $16.15. The firm recently confirmed that it has signed agreements with Cox Automotive U.K. (“Cox”) and Rivus Fleet Solutions for delivery, servicing, fleet management and reselling programs in the United Kingdom. It has been trading in a 52-week range of $8.70 to $23.63.
    Immutep Limited (IMMP) stock soared 89.35% to $4.09 in the pre-market trading after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. The most recent rating by B. Riley FBR, on September 28, 2018, is a Buy.
    Remark Holdings Inc. (MARK), a Internet Content & Information company, rose about 3.09% at $1.67 in pre-market trading Thursday after reporting that Remark’s KanKan AI business successfully released its edge computing systems, the S and T Series Smart Boxes.
    Baidu Inc. (BIDU) gained over 2.42% at $155.26 in pre-market trading Thursday December 10, 2020. The firm recently released new intelligent vehicle solutions for automakers and several high-end intelligent driving products during the second Apollo Ecosystem Conference.
    Before the trading started on December 10, 2020, Editas Medicine Inc. (EDIT) is up 9.13% to reach $55.2 after reporting submission of IND application for EDIT-301 with the FDA. It has been trading in a 52-week range of $14.01 to $43.65.
    Artelo Biosciences Inc. (ARTL) stock plunged -2.47% to $0.66 in the pre-market trading. The healthcare firm recently declared that it has filed a composition of matter patent application directed to a new solid dosage formulation, including its method of use, with the UK Patent Office.
    AquaBounty Technologies Inc. (NASDAQ: AQB) shares are trading down -17.07% at $7.19 at the time of writing following the selection of Innovasea as the Recirculating Aquaculture Systems (“RAS”) technology provider for its planned 10,000 metric ton farm. Company’s 52-week ranged between $1.52 to $11.40. Analysts have a consensus price target of $5.
    Pluristem Therapeutics Inc. (PSTI) lost over -5.57% at $6.61 in pre-market trading Thursday December 10, 2020 after declaring DMC recommendation following interim analysis of its phase III CLI study.
    Before the trading started on December 10, 2020, Veru Inc. (VERU) is up 25.96% to reach $4.9 after reporting that it has exclusively licensed worldwide rights to enobosarm, a late-stage oral novel androgen receptor (AR) targeting agent for the treatment of endocrine resistant ER+ HER2- metastatic breast cancer. It has been trading in a 52-week range of $2.10 to $4.74.
    Uranium Energy Corp. (AMEX: UEC) shares are trading down -4.32% at $1.33 at the time of writing. Company’s 52-week ranged between $0.35 to $1.59. Analysts have a consensus price target of $1.50.
    Boxlight Corporation (BOXL), a Communication Equipment company, rose about 7.23% at $1.78 in pre-market trading Thursday. The firm recently confirmed that they are the recipients of three THE Journal’s Best New EdTech Product Awards.
    Regulus Therapeutics Inc. (RGLS) stock moved up 19.34 percent to $1.07 in the pre-market trading. The company lately announced closing of $19.4 million private placement of equity.
    Before the trading started on December 10, 2020, Sea Limited (SE) is down -3.3% to reach $196.0 after reporting that it proposes to offer 11,000,000 American Depositary Shares, each representing one Class A ordinary share of the Company, in an underwritten public offering. It has been trading in a 52-week range of $35.61 to $207.51.
    Barclays PLC (NYSE: BCS) shares are trading down -3.85% at $7.5 at the time of writing. The firm recently revealed the launch of BARX Book for Equities, a new single-dealer platform developed in partnership with Nasdaq (Nasdaq: NDAQ). Company’s 52-week ranged between $3.41 to $10.22.
    Qualigen Therapeutics Inc. (QLGN) stock moved up 13.85 percent to $4.44 in the pre-market trading. The company recently announced board member Amy Broidrick as EVP, Chief Strategy Officer and named Sidney Emery, Jr. to its board.